CurvaFix completed an oversubscribed Series B private equity financing, totaling $10.75 million. Proceeds will support completion of the RESTORE Clinical Study and commercialization activities for the CurvaFix® Rodscrew System.
The system is designed for use in minimally invasive procedures in curved bones. The first implant is focused on improving outcomes and simplifying procedures to treat pelvic fractures, in which straight screws and invasive bone plates may result in suboptimal bone fixation of the curved pelvis. The CurvaFix Intramedullary Rodscrew is the first implant capable of following the natural bone curvature of the pelvis.
The device has received FDA 510(k) clearance in 2019 for fixation of pelvic fractures, and is currently the focus of the CurvaFix sponsored RESTORE Study which is gathering clinical evidence to support potential benefits for pelvic fracture patients in advance of a U.S. commercial launch.
The round was led by Sectoral Asset Management and included participation from existing investors, including Delta Dental Washington Seed Fund, and board members.